24,202 Shares in Bruker Corporation $BRKR Purchased by SteelPeak Wealth LLC

SteelPeak Wealth LLC acquired a new stake in Bruker Corporation (NASDAQ:BRKR) in the first quarter, Holdings Channel reports. The fund acquired 24,202 shares of the medical research company’s stock, valued at approximately $875,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in BRKR. Los Angeles Capital Management LLC bought a new position in shares of Bruker during the fourth quarter worth approximately $26,000. Allworth Financial LP raised its position in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after buying an additional 257 shares in the last quarter. Parallel Advisors LLC boosted its stake in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after buying an additional 479 shares during the period. Summit Securities Group LLC bought a new stake in shares of Bruker in the fourth quarter valued at approximately $50,000. Finally, Covestor Ltd grew its position in Bruker by 304.6% during the fourth quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock worth $67,000 after buying an additional 1,066 shares in the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Bruker Stock Performance

NASDAQ BRKR opened at $58.23 on Friday. The firm’s 50 day simple moving average is $54.72 and its 200 day simple moving average is $45.90. The firm has a market capitalization of $8.86 billion, a price-to-earnings ratio of -242.62, a P/E/G ratio of 1.86 and a beta of 1.29. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67. Bruker Corporation has a 1 year low of $28.53 and a 1 year high of $64.54.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The business had revenue of $823.40 million during the quarter, compared to the consensus estimate of $795.62 million. During the same period in the previous year, the business earned $0.47 earnings per share. The company’s revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, research analysts expect that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were paid a $0.05 dividend. The ex-dividend date was Monday, June 22nd. This represents a $0.20 annualized dividend and a dividend yield of 0.3%. Bruker’s dividend payout ratio (DPR) is presently -83.33%.

Analyst Ratings Changes

BRKR has been the topic of a number of recent research reports. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. UBS Group set a $60.00 target price on Bruker in a research report on Wednesday, June 24th. Stifel Nicolaus set a $45.00 target price on Bruker in a report on Friday, May 8th. Leerink Partners raised their price target on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. boosted their price target on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Bruker currently has an average rating of “Hold” and an average target price of $56.79.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.